InVivo Therapeutics Corporation (NVIV) Announces CEO Mark Perrin Named Chairman Of The Board

InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Mark D. Perrin as Chairman of InVivo's Board of Directors, effective immediately. Perrin has served as a Board member and Chief Executive Officer of the company since January 2014. John A. McCarthy, Jr., current non-executive Chairman of the Board since September 2013, will remain on the Board and will continue to chair the Audit Committee.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.